Drug Trial Radar · NCT00525707
Tezosentan in Acute Heart Failure
Last checked: Nov 20, 2026Latest source record: Jul 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
735
Actual
Start
Apr 2003
Primary completion
Jan 2005
Study completion Jan 2005
Sponsor
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 6, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The randomized patients with acute heart failure will be stratified based on the presence or absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the first 30 minutes and 1 mg/h thereafter or matching placebo in a 1:1 manner. The duration of the treatment is 24 hours up to 72 hours. The duration of the follow-up period is 30 days after treatment initiation for death, re-hospitalizations and SAEs followed by a follow-up period of 5 months for vital status.
Conditions
- Acute Heart Failure
- Acute Decompensation of Chronic Heart Failure
- New Onset of Heart Failure
Interventions
tezosentanDrug
tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of death or worsening heart failureTime frame: 7 days following study drug initiation
Locations
35 sites in 10 countries. Site status is shown where the registry gives one.
University of Alabama-Birmingham
Birmingham, Alabama
Advanced Heart Failure and Transplant Service, Palo Alto VA Health Care System, Cardiology Section
Palo Alto, California
Denver VAMC
Denver, Colorado
The Heart Hospital at Alledgheny General, Division of Cardiology
Pittsburgh, Pennsylvania
Veterans Affairs Medical Center
Houston, Texas
Tyler Cardiovascular Consultants
Tyler, Texas
Danville Medical Center
Danville, Virginia
Medical Associates, Bellebue
Bellevue, Washington
AKH University of Vienna, Abt. Medizinische Kardiologie
Vienna, Austria
Roskilde Amt Sygehus
Roskilde, Denmark
Hopital Ambroise Pare, Service de Cardiologie
Boulogne, France
Heart Failure clinic C.H. Dubos
Pontoise, France
Hopitaux Universitaires de Strasbourg, Hopital Hautepierre
Strasbourg, France
CHU Rangueil, Cardiologie A
Toulouse, France
Medizinische Klinik I, Universitatsklinikum Aachen
Aachen, Germany
Campus Virchow-Klinikum, Medizinishe Klinik mit Schwerpunkt Kardiologie
Berlin, Germany
Georg-August-Universitat Gottingen, Zentrum fur Innere Med
Göttingen, Germany
Dept. of Cardiology, University of Athens, Alexandra Hospital
Athens, Greece
Barzilai Hospital
Ashkelon, Israel
Carmel Medical Center
Haifa, Israel
Wolfson Medical Center
Holon, Israel
Hadassah Hospital
Jerusalem, Israel
Nazareth Hospital EMMS
Nazareth, Israel
Assaf-Harofeh Medical Center
Tsrifin, Israel
Klinika Kardiologii i Chorob Wewnetrznych, Samodzielny Publiczny Szpital
Bydgoszcz, Poland
Klinika Chorob Serca, Akademia Medyczna w Gdansku
Gdansk, Poland
I Klinika Kardiolgii, Collegium Medicum UJ
Krakow, Poland
Institute of Cardiology College, College of Medicine of Jagellonian University
Krakow, Poland
Kategra I Klinika Kardiolgii AM
Wroclaw, Poland
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Switzerland
Cardio Centro Ticino, Servizio Cardiovasculare
Lugano, Switzerland
University Hospital Zurich
Zurich, Switzerland
Glasgow Royal Infirmary
Glasgow, United Kingdom
Hull Royal Infirmary
Hull, United Kingdom
Scunthorpe General Hospital
Scunthorpe, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.